abstract |
Ophthalmic formulations containing tyrosine kinase inhibitors are described, such as Nintedanib, Axitinib, Sorafenib and Pazopanib; ophthalmic formulations may contain microparticles or nanoparticles of the tyrosine kinase inhibitor; Methods for using ophthalmic formulations to treat ocular surface diseases, such as pterygium, including recurrent pterygium and hyperemia associated with pterygium are also described. |